Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20148862 | 0.89 | L3MBTL1 (0.79) | L3MBTL1GAAMAPTALDH1A1ALOX15 | |
| SCHEMBL9851540 | 0.87 | TSHR (0.65) | L3MBTL1GAATSHRTP53PLA2G4B | |
| SCHEMBL9851566 | 0.84 | MAPT (0.74) | L3MBTL1GAAMAPTALDH1A1NPC1 | |
| SCHEMBL9923551 | 0.83 | L3MBTL1 (0.65) | L3MBTL1GAAALDH1A1NPC1 | |
| SCHEMBL15887752 | 0.82 | GAA (0.83) | L3MBTL1GAAMAPTTSHRTP53 | |
| SCHEMBL12534316 | 0.81 | KMT2A (0.56) | L3MBTL1GAAMAPTALDH1A1USP2 | |
| SCHEMBL21093476 | 0.81 | L3MBTL1 (0.52) | L3MBTL1GAAMAPTALDH1A1NPC1 | |
| SCHEMBL13692338 | 0.81 | KDM4E (0.55) | L3MBTL1GAAALDH1A1 | |
| SCHEMBL4055883 | 0.81 | L3MBTL1 (0.61) | L3MBTL1TSHRNPC1ALOX15MAPK1 | |
| SCHEMBL16156097 | 0.81 | TSHR (0.71) | L3MBTL1GAATSHRTP53PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576119-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | claimed |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | claimed |
| US-7202264-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | claimed |
| EP-1670810-A2 | GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLI CSUGAR MOIETIES AT THE TERMINI | Isis Pharmaceuticals, Inc. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050208588-A1 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | claimed |
| US-20050059066-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | IONIS PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | claimed |
| WO-2005023825-A2 | GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLIC SUGAR MOIETIES AT THE TERMINI | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| US-20050053981-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | ISIS PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | claimed |
| US-20040242897-A1 | Universal support media for synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004011474-A1 | UNIVERSAL SUPPORT MEDIA FOR SYNTHESIS OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2004-02-05 | — | — | WO | claimed |
| US-6653468-B1 | Bicyclic heptane derivatives linked to controlled pore glass or copolymers of polystyrene; can be cleaved and used for subsequent reactions | ISIS PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | claimed |
| US-6239220-B1 | Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. | 2001-05-29 | — | — | US | claimed |
| US-6124484-A | Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-26 | — | — | US | claimed |
| JP-H09510206-A | — | — | 1997-10-14 | — | — | JP | claimed |
| US-5623068-A | Synthesis of DNA using substituted phenylacetyl-protected nucleotides | BECKMAN INSTRUMENTS, INC. (US) | 1997-04-22 | — | — | US | claimed |
| EP-0749436-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1996-12-27 | — | — | EP | claimed |
| EP-0725787-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-08-14 | — | — | EP | claimed |
| WO-1996006853-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-03-07 | — | — | WO | claimed |
| WO-1995024413-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1995-09-14 | — | — | WO | claimed |
| EP-3160476-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTION | JANSSEN BIOPHARMA INC (US) | 2020-09-30 | — | — | EP | disclosed |
| US-RE48171-E1 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-08-25 | — | — | US | disclosed |
| US-9862743-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9603864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9603863-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9605018-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9598457-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9441007-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9422322-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9365605-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9346848-B2 | Azido nucleosides and nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9303055-B2 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-04-05 | — | — | US | disclosed |
| US-9278990-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20160039858-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160039861-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-9249174-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20160016987-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
| US-20150366887-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
| US-20150183819-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20150141363-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150105341-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-04-16 | — | — | US | disclosed |
| US-8980865-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150051167-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2015-02-19 | — | — | US | disclosed |
| US-20150038451-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
| US-20150005251-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV | 2015-01-01 | — | — | US | disclosed |
| US-8877731-B2 | Azido nucleosides and nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8871737-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140303108-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8703728-B2 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | ISIS PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-1562971-B1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS INC (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20130261026-A1 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-10-03 | — | — | US | disclosed |
| US-8541599-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8461317-B2 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120165547-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8153725-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC (US) | 2012-04-10 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-8124745-B2 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | ISIS PHARMACEUTICALS, INC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120029166-A1 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORTS | THE REGENTS OF THE UNVERSITY OF MICHIGAN (US) | 2012-02-02 | — | — | US | disclosed |
| US-8053187-B2 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-11-08 | — | — | US | disclosed |
| US-20110097762-A1 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORTS | THE REGENTS OF THE UNVERSITY OF MICHIGAN (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7807807-B2 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100234528-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100216982-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | Isis Pharmaceutiacls, Inc. (US) | 2010-08-26 | — | — | US | disclosed |
| US-7718810-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20100093974-A1 | Linkers and Co-Coupling Agents for Optimization of Oligonucleotide Synthesis and Purification on Solid Supports | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-04-15 | — | — | US | disclosed |
| US-7696345-B2 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | ISIS PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20100029513-A1 | Methods And Compositions For Generating Mixtures Of Nucleic Acid Molecules | AGILENT TECHNOLOGIES, INC. | 2010-02-04 | — | — | US | disclosed |
| US-7576119-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7553958-B2 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090131682-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| EP-2048149-A2 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid support | The Regents of the University of Michigan (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20090075840-A1 | Methods And Compositions For Generating Mixtures Of Nucleic Acid Molecules | AGILENT TECHNOLOGIES, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20080039618-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | ALLERSON CHARLES | 2008-02-14 | — | — | US | disclosed |
| EP-1373286-A4 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORT | UNIV MICHIGAN (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20070287832-A1 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | GAO, XIAOLIAN | 2007-12-13 | — | — | US | disclosed |
| US-7211654-B2 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-01 | — | — | US | disclosed |
| US-7202264-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1670810-A2 | GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLI CSUGAR MOIETIES AT THE TERMINI | Isis Pharmaceuticals, Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050208588-A1 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| US-20050059066-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | IONIS PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005023825-A2 | GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLIC SUGAR MOIETIES AT THE TERMINI | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050053981-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | ISIS PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
| US-20040242897-A1 | Universal support media for synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040171570-A1 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | IONIS PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
| WO-2004011474-A1 | UNIVERSAL SUPPORT MEDIA FOR SYNTHESIS OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| EP-1373286-A2 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORT | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2004-01-02 | — | — | EP | disclosed |
| US-6653468-B1 | Bicyclic heptane derivatives linked to controlled pore glass or copolymers of polystyrene; can be cleaved and used for subsequent reactions | ISIS PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | disclosed |
| EP-0843684-B1 | UNIVERSAL SOLID SUPPORTS AND METHODS FOR THEIR USE | BECKMAN COULTER INC (US) | 2003-08-20 | — | — | EP | disclosed |
| US-20030120035-A1 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2003-06-26 | — | — | US | disclosed |
| WO-2002072791-A2 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORT | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2002-09-19 | — | — | WO | disclosed |
| US-6239220-B1 | Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. | 2001-05-29 | — | — | US | disclosed |
| US-5869696-A | OLIGONUCLEOTIDE CLEAVING REAGENT CONSISTING OF AQUEOUS SOLUTION OF METHYLAMINE AND AQUEOUS SOLUTION OF DIMETHYLAMINE OR TRIMETHYLAMINE | BECKMAN INSTRUMENTS, INC. (US) | 1999-02-09 | — | — | US | disclosed |
| EP-0839829-A2 | Universal solid support oligonucleotide reagents | BECKMAN INSTRUMENTS, INC. (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5623068-A | Synthesis of DNA using substituted phenylacetyl-protected nucleotides | BECKMAN INSTRUMENTS, INC. (US) | 1997-04-22 | — | — | US | disclosed |
| EP-0749436-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5574146-A | Oligonucleotide synthesis with substituted aryl carboxylic acids as activators | BECKMAN INSTRUMENTS, INC. (US) | 1996-11-12 | — | — | US | disclosed |
| WO-1995024413-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| US-5410068-A | Protecting groups for natural products | PERSEPTIVE BIOSYSTEMS, INC. (US) | 1995-04-25 | — | — | US | disclosed |
| EP-0424819-B1 | Reversible modification of biological compounds for detection, separation and purification thereof | MILLIPORE CORP (US) | 1994-12-28 | — | — | EP | disclosed |
| EP-0424819-B1 | Reversible modification of biological compounds for detection, separation and purification thereof | MILLIPORE CORP (US) | 1994-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (37 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120035-A1 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | PCNA, LIG4, DCLRE1A | L3MBTL1 1367/4885GAA 2820/4885MAPT 3889/4885 |
| US-20040171570-A1 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | HNRNPC, SNRPE, IGF2BP1 | L3MBTL1 625/4885GAA 2544/4885MAPT 4440/4885 |
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | L3MBTL1 1351/4885GAA 439/4885MAPT 4521/4885 |
| US-20140303108-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | L3MBTL1 1541/4885GAA 1499/4885MAPT 4861/4885 |
| US-20130261026-A1 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORTS | PCNA, LIG4, DCLRE1A | L3MBTL1 1367/4885GAA 2820/4885MAPT 3889/4885 |
| US-20160039858-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | L3MBTL1 1351/4885GAA 439/4885MAPT 4521/4885 |
| US-20120029166-A1 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORTS | PCNA, LIG4, DCLRE1A | L3MBTL1 1367/4885GAA 2820/4885MAPT 3889/4885 |
| US-20090131682-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | L3MBTL1 2447/4885GAA 2060/4885MAPT 301/4885 |
| US-20100216982-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | HNRNPC, SNRPE, IGF2BP1 | L3MBTL1 625/4885GAA 2544/4885MAPT 4440/4885 |
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | L3MBTL1 1476/4885GAA 535/4885MAPT 3605/4885 |
| US-20120165547-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | L3MBTL1 2447/4885GAA 2060/4885MAPT 301/4885 |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | RNASEL, RNASE1, RNASEH1 | L3MBTL1 219/4885GAA 139/4885MAPT 4780/4885 |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | L3MBTL1 2447/4885GAA 2060/4885MAPT 301/4885 |
| US-20100029513-A1 | Methods And Compositions For Generating Mixtures Of Nucleic Acid Molecules | POLM, RNGTT, POLN | L3MBTL1 527/4885GAA 437/4885MAPT 3734/4885 |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | L3MBTL1 388/4885GAA 965/4885MAPT 4059/4885 |
| US-20150051167-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | L3MBTL1 962/4885GAA 901/4885MAPT 3302/4885 |
| US-20150105341-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | L3MBTL1 1218/4885GAA 606/4885MAPT 3367/4885 |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | L3MBTL1 388/4885GAA 965/4885MAPT 4059/4885 |
| US-20160016987-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | L3MBTL1 1351/4885GAA 439/4885MAPT 4521/4885 |
| US-20100234528-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | L3MBTL1 2447/4885GAA 2060/4885MAPT 301/4885 |
| US-20050059066-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | OGG1, UNG, PCNA | L3MBTL1 1450/4885GAA 239/4885MAPT 2702/4885 |
| US-20050053981-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | OGG1, UNG, PCNA | L3MBTL1 1450/4885GAA 239/4885MAPT 2702/4885 |
| US-20080039618-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | HNRNPC, SNRPE, IGF2BP1 | L3MBTL1 625/4885GAA 2544/4885MAPT 4440/4885 |
| US-20150141363-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | L3MBTL1 388/4885GAA 965/4885MAPT 4059/4885 |
| US-20150366887-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | L3MBTL1 590/4885GAA 577/4885MAPT 4077/4885 |
| US-20160039861-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | L3MBTL1 1351/4885GAA 439/4885MAPT 4521/4885 |
| US-20050208588-A1 | Supports for oligomer synthesis | ILK, NOP2, PFAS | L3MBTL1 2447/4885GAA 2060/4885MAPT 301/4885 |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | L3MBTL1 868/4885GAA 622/4885MAPT 4482/4885 |
| US-20150038451-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | L3MBTL1 388/4885GAA 965/4885MAPT 4059/4885 |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | PNP, TYMP, NTPCR | L3MBTL1 963/4885GAA 488/4885MAPT 4701/4885 |
| US-20070287832-A1 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | PCNA, LIG4, DCLRE1A | L3MBTL1 1367/4885GAA 2820/4885MAPT 3889/4885 |
| US-20100093974-A1 | Linkers and Co-Coupling Agents for Optimization of Oligonucleotide Synthesis and Purification on Solid Supports | PCNA, LIG4, DCLRE1A | L3MBTL1 1367/4885GAA 2820/4885MAPT 3889/4885 |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | L3MBTL1 3565/4885GAA 532/4885MAPT 4329/4885 |
| US-20150005251-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NT5C2 | L3MBTL1 1005/4885GAA 743/4885MAPT 3858/4885 |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | L3MBTL1 1450/4885GAA 496/4885MAPT 2729/4885 |
| US-20150183819-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | L3MBTL1 3565/4885GAA 532/4885MAPT 4329/4885 |
| US-20040242897-A1 | Universal support media for synthesis of oligomeric compounds | NEFM, POLRMT, POLM | L3MBTL1 2442/4885GAA 3825/4885MAPT 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.